Drug Database
Back to search

Netherlands· NL-b052bd9ff50b

Livmarli 30 mg, tabletten

A maralixibat chloride product containing maralixibatchloride, registered in Netherlands by Mirum Pharmaceuticals International B.V.. The same ATC class is registered in 11 of our 19 countries.

ATC A05AX04

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedLivmarli 30 mg, tablettenATCA05AX04REGISTER NO.NL-b052bd9ff50bPACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about maralixibatchlorideAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Maralixibat chloride is registered in 11 of 19 countries.

Countries holding a registration under ATC A05AX04 (maralixibat chloride), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 6 of them publish a price we can compare per daily dose
Search maralixibat chloride products by name

Maralixibat chloride · ATC A05AX04

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
MARALIXIBATCHLORIDE
Manufacturer
Mirum Pharmaceuticals International B.V.
Country
Netherlands (NL)
ATC code
A05AX04
ATC class
Maralixibat chloride
Defined daily dose
28.5 mg, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/22/1704

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same class

Other records under A05AX04

Maralixibat chloride, as other registers publish it.

All maralixibat chloride products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b1fa11ce-5d1a-4070-a620-5ff1daed6b1a
GET /v1/drugs/b1fa11ce-5d1a-4070-a620-5ff1daed6b1a?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/livmarli-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Maralixibat chloride",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp134245",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "CROSPOVIDON (E 1202)",
    "GLYCEROLPALMITOSTEARAAT",
    "LACTOSE 1-WATER",
    "SILICIUMDIOXIDE (E 551)"
  ],
  "substances": [
    "MARALIXIBATCHLORIDE"
  ],
  "leaflet_url": null,
  "authorised_at": "2022/12/09",
  "procedure_number": "EMEA/H/C/005857",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/22/1704",
  "additional_monitoring": "Y"
}
API referenceMCP serverPlans

See everything about maralixibat chloride.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console